Viva Biotech Holdings (FRA:VB0) Owner Earnings per Share (TTM): 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VB0 Viva Biotech Holdings FRA:VB0
47 GF Score
Price €0.14
GF Value €0.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Viva Biotech Holdings Owner Earnings per Share (TTM)?

Viva Biotech Holdings FRA:VB0 +0.70% 47 Owner Earnings per Share (TTM) is 0.00 as of Dec. 2025. GuruFocus rates FRA:VB0 with a GF Score™ of 47/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 207 Biotechnology companies, Viva Biotech Holdings ranks worse than 58.94% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Viva Biotech Holdings's Owner Earnings per Share (TTM) ended in Dec. 2025 was €0.00. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Viva Biotech Holdings's Owner Earnings per Share (TTM) or its related term are showing as below:

FRA:VB0' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 24.24   Med: 61.79   Max: 523.33
Current: 31.54


During the past 10 years, the highest Price-to-Owner-Earnings ratio of Viva Biotech Holdings was 523.33. The lowest was 24.24. And the median was 61.79.


FRA:VB0's Price-to-Owner-Earnings is ranked worse than
58.94% of 207 companies
in the Biotechnology industry
Industry Median: 23.63 vs FRA:VB0: 31.54

Viva Biotech Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was €0.01. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01. It's PE Ratio (TTM) ratio for today is 13.09.

Viva Biotech Holdings's EPS without NRI for the six months ended in Dec. 2025 was €0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.01. It's PE Ratio without NRI ratio for today is 10.29.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Viva Biotech Holdings Owner Earnings per Share (TTM) Related Terms


Viva Biotech Holdings Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Viva Biotech Holdings's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viva Biotech Holdings Owner Earnings per Share (TTM) Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.04 -0.01 0.00 0.00

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 0.00 0.00 0.00

FRA:VB0 vs VRTX, REGN, ALNY: Owner Earnings per Share (TTM) Comparison

For the Biotechnology subindustry, Viva Biotech Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings Price-to-Owner-Earnings vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Price-to-Owner-Earnings falls into.


FRA:VB0
47GF Score
Viva Biotech Holdings FRA:VB0
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viva Biotech Holdings Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Viva Biotech Holdings's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 26.6
Depreciation, Depletion and Amortization 25.6
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 29.2
Change In Working Capital -14.5
Shares Outstanding (Diluted Average) 2,339.3

1. Start with "Net Income" from income statement. Viva Biotech Holdings's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was €26.6 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Viva Biotech Holdings's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 was €25.6 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Viva Biotech Holdings's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = €29.2 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Viva Biotech Holdings's 5-Year Average Maintenance Capital Expenditure = €29.2 Mil

5. "Change In Working Capital" is from cashflow statement. Viva Biotech Holdings's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was €-14.5 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Viva Biotech Holdings's Shares Outstanding (Diluted Average) for the months ended in Dec. 2025 was 2339.346 Mil.

Viva Biotech Holdings's Onwer Earnings Per Share for Dec. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 26.646 +25.59+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-29.16+-14.498)/2339.346
=0.00

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.144/0.00
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 0.00 mean?
Viva Biotech Holdings (FRA:VB0) has a Owner Earnings per Share (TTM) of 0.00 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Viva Biotech Holdings. Over the past decade, Viva Biotech Holdings' Owner Earnings per Share (TTM) has ranged from 24.24 to 523.33. According to the industry distribution chart, Viva Biotech Holdings ranks #122 out of 207 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Viva Biotech Holdings' Owner Earnings per Share (TTM) too high?
Viva Biotech Holdings' current Owner Earnings per Share (TTM) is 0.00. Over the past 10 years, this metric has ranged from a low of 24.24 to a high of 523.33. Based on the distribution chart, Viva Biotech Holdings ranks #122 out of 207 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Owner Earnings per Share (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #122 out of 207 companies for Owner Earnings per Share (TTM). This places Viva Biotech Holdings in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.63. Historically, Viva Biotech Holdings' own Owner Earnings per Share (TTM) has ranged from 24.24 to 523.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Biotechnology company?
The median Owner Earnings per Share (TTM) among Biotechnology companies is 23.63, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Viva Biotech Holdings. For the Biotechnology industry, the median Owner Earnings per Share (TTM) is 23.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Owner Earnings per Share (TTM) is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.14 — trading 60% above its estimated fair value. The current Owner Earnings per Share (TTM) is 0.00. Viva Biotech Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Owner Earnings per Share (TTM) is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?

Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued. The current stock price of €0.14 is trading 60% above its estimated GF Value™ of €0.09. GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.

Key valuation signals for FRA:VB0:

  • Owner Earnings per Share (TTM): 0.00
  • GF Value™: €0.09 vs. price of €0.14 (60% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viva Biotech Holdings Business Description

Other Exchanges VBIZF:USA01873:Hong Kong
Address 735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
47GF Score

Get the complete analysis for FRA:VB0

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price
€0.09
GF Value